September 27, 2019 / 5:26 PM / 2 months ago

BRIEF-Health Canada Approves Hoffmann-La Roche's Tecentriq In Combination With Chemotherapy For Breast Cancer

Sept 27 (Reuters) - Hoffmann-La Roche Limited

* HEALTH CANADA APPROVES TECENTRIQ® IN COMBINATION WITH CHEMOTHERAPY (NAB-PACLITAXEL) AS FIRST IMMUNOTHERAPY TREATMENT FOR AGGRESSIVE FORM OF BREAST CANCER(1)

* HOFFMANN-LA ROCHE - HEALTH CANADA APPROVED TECENTRIQ IN COMBINATION WITH CHEMOTHERAPY FOR TREATMENT OF PATIENTS WITH LOCALLY ADVANCED BREAST CANCER Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below